ReviewMolecules (Basel, Switzerland)2023
Mesoporous Drug Delivery System: From Physical Properties of Drug in Solid State to Controlled Release.
Review in Molecules (Basel, Switzerland), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed.
- Dual metabolic checkpoint blockadeBioactive materials · 2027Article
- Systematic Investigation on Particle and Pore Size Effects of Mesoporous Silica on Molecular Mobility and Physical Stability of Overloaded Amorphous Acetaminophen.Molecular pharmaceutics · 2026Article
- Biomimetic TME-Responsive Nanotheranostics for Precise NIR-II Ratiometric Photoacoustic Imaging and Synergistic Immuno-Photothermal Therapy.Small (Weinheim an der Bergstrasse, Germany) · 2026Article
- Microwave-Assisted Wet Granulation for Engineering Rice Starch-Mannitol Co-Processed Excipients for Direct Compression of Orally Disintegrating Tablets.Pharmaceutics · 2026Article
- Solidification of SNEDDS Using Mesoporous Carriers (2020-2025): A Review of Design, Biopharmaceutical Enhancement, and Therapeutic Impact.Drug design, development and therapy · 2025Review
- Functionalized Periodic Mesoporous Silica Nanoparticles for Inhibiting the Progression of Atherosclerosis by Targeting Low-Density Lipoprotein Cholesterol.Pharmaceutics · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Mesoporous materials, which exhibit great potential in the control of polymorphs and delivery of poorly water-soluble drugs, have obtained considerable attention in the field of pharmaceutical science. The physical properties and release behaviors of amorphous or crystalline drugs may be affected by formulating them into mesoporous drug delivery systems. In the past few decades, an increasing amount of papers have been written about mesoporous drug delivery systems, which play a crucial role in improving the properties of drugs. Herein, mesoporous drug delivery systems are comprehensively reviewed in terms of their physicochemical characteristics, control of polymorphic forms, physical stability, in vitro performance, and in vivo performance. Moreover, the challenges and strategies of developing robust mesoporous drug delivery systems are also discussed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.